Related Experiment Videos
Visfatin: the missing link between intra-abdominal obesity and diabetes?
Jaswinder K Sethi1, Antonio Vidal-Puig
1Department of Clinical Biochemistry, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QR, UK.
Trends in Molecular Medicine
|July 12, 2005
Summary
Visfatin, a novel adipokine from visceral fat, shows insulin-mimetic actions. Understanding visfatin may unlock new treatments for obesity-related diabetes and metabolic syndrome.
Area of Science:
- Endocrinology
- Metabolic Research
- Adipose Tissue Biology
Background:
- Obesity-related diabetes and metabolic disorders are linked to increased visceral adipose tissue.
- Differences between visceral and subcutaneous fat depots are crucial for therapeutic strategies.
- Visfatin (pre-B-cell colony-enhancing factor, PBEF) is a novel adipokine preferentially produced by visceral fat.
Purpose of the Study:
- To explore the role of visfatin in obesity-induced insulin resistance.
- To investigate the potential of visfatin as a therapeutic target for type 1 and type 2 diabetes.
- To discuss the advantages and disadvantages of visfatin's actions in metabolic syndrome.
Main Methods:
- Literature review on visfatin's biological actions.
- Analysis of visfatin's role in insulin-mimetic effects.
- Discussion of visfatin's implications for future diabetes and metabolic syndrome therapies.
Main Results:
- Visfatin exhibits insulin-mimetic properties.
- Preferential production of visfatin by visceral adipose tissue.
- Visfatin's dual role in metabolic regulation warrants further investigation.
Conclusions:
- Visfatin's insulin-mimetic actions suggest potential therapeutic benefits for diabetes.
- Further research is needed to fully understand visfatin's complex role and therapeutic potential.
- Targeting visfatin may offer novel strategies for managing obesity-related metabolic disorders.